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ABSTRACT
The COVID-19 pandemic caused by SARS-CoV-2 has resulted in millions of cases and hundreds of 
thousands of deaths. Beyond there being no available antiviral therapy, stimulating protective immunity 
by vaccines is the best option for managing future infections. Development of a vaccine for a novel virus is 
a challenging effort that may take several years to accomplish. This mini-review summarizes the immu-
nopathological responses to SARS-CoV-2 infection and discusses advances in the development of vac-







The 2019 coronavirus disease (COVID-19) was first reported in 
late December 2019 in Wuhan; China has now become a global 
pandemic. The virus causing COVID-19 is the Severe acute 
respiratory coronavirus syndrome 2 (SARS-CoV-2) that belongs 
to the coronaviridae family of viruses. The characteristic feature of 
coronavirus is the presence of club-like extensions on the surface 
made of glycosylated trimers of S protein. The coronaviruses are 
roughly 80–120 nm in diameter.1 COVID-19 resulting from the 
new SARS-CoV-2 infection has now become a global health 
concern. The incubation time of the virus is about 2–10 days, 
and it is transmitted through aerosol from human-to-human and 
also through contaminated inanimate objects and hands.2 The 
virus can remain infective on the surfaces of objects for up to 
9 days at room temperature. However, the viral survival declines 
with temperatures above 30°C. It can be efficiently inactivated by 
surface disinfection procedures with 62–71% ethanol, 0.5% hydro-
gen peroxide or 0.1% sodium hypochlorite within 1 minute.2
First described in China, SARS-CoV-2 has been reported in 
essentially all countries worldwide, with more than 15 million 
infected subjects and more than a half-million deaths. Owing 
to the global spread, WHO declared COVID-19 as a pandemic 
on 11 March 2020.3
Since the first report of the genomic sequence of the SARS- 
CoV-2 has come, researchers, clinicians, and pharmaceutical 
companies have devoted all their resources and research 
toward developing therapeutic modalities and vaccines for 
SARS-CoV-2.
Most of the data on antiviral therapy is based on the clinical 
and preclinical studies on other related viruses such as SARS- 
CoV, Middle East coronavirus respiratory syndrome (MERS- 
CoV) and non-coronavirus (Ebola). This narrative mini-review 
summarizes epidemiology, pathogenesis, immune responses, 
vaccine development issues, and immunotherapy for 
COVID-19 and provides an update on recent advances for 
vaccine and immunotherapy.
Pathogenesis
The SARS-CoV-2 resembles the SARS-CoV in several aspects. 
Homology modeling revealed that both the viruses employ 
similar receptor-binding domains to attach to the host cells 
with subtle differences in particular amino acid residues.4 The 
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coronaviruses have spike proteins that are glycoproteins and 
consist of two subunits: S1 and S2. The S1 and S2 proteins are 
the most important structural proteins of the virus. The spikes 
on the surface of the SARS-CoV-2 are homotrimers of 
S proteins that establish attachments with the host cell 
receptors.5 The structural and the non-structural proteins 
(nsps) in co-ordination carry out the CoV pathogenesis and 
decide the virulence.6
The virus entry
Coronaviruses enter into the host cells by using the viral S protein.7 
SARS-CoV-2 enters into the host cell by the interaction of its 
S protein with the host receptor “ACE2” present in most of the 
human cell types.8 The viral RNA is transferred into the host cell 
cytoplasm as soon as it enters the host cell. The viral genome 
translates its two polyproteins and structural proteins. These pro-
teins enable the viral genome to replicate inside the host cell.9 The 
nascent viral glycoprotein envelope is processed in the endoplas-
mic reticulum or Golgi membrane. Then, the genomic RNA and 
the nucleocapsid proteins fuse to form the nucleocapsid. The 
newly formed viral particles then fuse with the vesicles in the 
intermediate reticulum-Golgi endoplasmic compartment 
(ERGIC) followed by the fusion of these virus-containing vesicles 
with the plasma membrane that leads to the virus release.7
Antigen presentation
To date, there are no reported studies on the immune mechan-
ism of SARS-CoV-2 infection. However, the studies on the 
immune mechanisms of the related viruses like SARS-CoV 
and MERS give much insight into the immune mechanism of 
the virus.10 Upon entry into the host, the virus presents its 
antigens to the antigen-presenting cells (APCs) of the host 
mediating the antiviral mechanism of the host immune system.
Humoral and cellular immunity
Antigen presentation by the APCs results in the activation of 
the cell-mediated and the humoral immunity of the host gov-
erned by T cells and B cells, respectively. The antibody 
response (levels of IgM and IgG) to SARS-CoV follows 
a characteristic pattern.11 The IgM antibody levels reach unde-
tectable levels by the end of 12th week of infection, but the IgG 
remains for more extended periods.12
SARS-CoV infection induces concomitant activation of T cell 
and B cell-mediated immune responses. Upon SARS-CoV infec-
tion, B cell responses are first observed against the nucleocapsid 
(N) protein followed by responses to S protein which is seen 
within 4–8 days after the onset of symptoms.13,14 Neutralizing 
antibody responses for the S protein begins by 2nd week. Many 
patients develop the neutralizing antibody responses by 3rd 
week.15,16 Since viral titers are observed to peak earlier for SARS- 
CoV-2 as compared to SARS-CoV, the antibody responses may 
also be elicited earlier.17,18 It has been observed that a subset of 
infected patients do not develop long-lasting antibody responses 
to SARS-CoV-2. However, it is not clear whether these patients 
are more susceptible for re-infection.19,20
It has been documented that the population of CD4 and CD8 
T cells significantly falls in the patients infected with SARS-CoV 
-2.21 It was seen that the antibody-secreting cells (ASCs) in the 
blood of a SARS-CoV-2-infected patient increased from day 7 
(1.48%) to a peak level on day 8 (6.91%). Similarly, the cTFH cells 
increased from 1.98% on day 7 to 3.25% on day 8. The cTFH cells 
peaked on 9th day (4.4.6%). This observation indicates that both 
humoral and cell-mediated immunity comes into play in 
response to SARS-CoV-2 infection.22
An accumulation of mononuclear cells suspected to be 
monocytes and T cells was observed in the lungs of a COVID- 
19 patient along with decreased systemic levels of hyperactive 
T cells.21 Lymphopenia and decreased levels of peripheral T cells 
indicate that the T cells are migrated toward the lungs from the 
systemic circulation to the site of infection (primarily lungs) to 
counteract the viral infection.23–26 Increased exhaustion and 
reduced functional diversity of T cells may be predictive of 
severe disease progression.27 It has been seen that the patients 
recovered from SARS-CoV developed coronavirus-specific 
memory T cells, seen up to 2 years after recovery.28,29 It is 
quite evident from these reports that T cell-mediated immunity 
plays an important role in controlling infection. However, sev-
eral vaccine agents designed against SARS-CoV resulted in 
immunopathology due to TH2 cell-mediated infiltration of 
eosinophils.30,31 The vaccinated mice showed increased immu-
nopathology than protection against SARS-CoV infection.32 
Therefore, further extensive studies are needed to evaluate the 
protective versus damaging T cell responses, which is essential 
for designing vaccines for the coronavirus.33 However, it is very 
important to investigate whether T cell-mediated responses are 
solely responsible for infection control in humans. This will 
provide impetus to the vaccine development process.
Cytokine storm
Acute respiratory distress syndrome (ARDS) is the most com-
mon pathology seen in patients infected with SARS-CoV-2, 
SARS-CoV, and MERS.21,34 A hyperinflammatory condition 
associated with hypercytokinaemia is often observed in 
COVID-19 patients.34 This hyperinflammatory condition is 
related to multiple organ failure.35 The cytokine surge seen in 
COVID-19 patients results due to increased levels of the proin-
flammatory cytokines such as IFN-a, IFN-g, IL-1b, IL-6, IL-12, 
IL-18, IL-33, TNF-a, TGFb and chemokines such as CCL2, 
CCL3, CCL5, CXCL8, CXCL9, CXCL10, among others, by 
the cells of immunity system.34,36 This cytokine storm may be 
followed by multiple organ failure and ARDS resulting in the 
death of the patients infected with SARS-COV-2 as seen in 
SARS-CoV and MERS-CoV infection.21
Evasion of the host immune response
As the SARS-CoV-2 is very new to the researchers, not much 
data are available on the immunopathological mechanisms and 
the tricks of the novel virus to escape the host immune 
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response. However, data from the studies on the previously 
known coronaviruses like SARS-CoV and MERS can be uti-
lized to speculate the possible mechanisms this new SARS-CoV 
-2 virus may employ to deceive the host immune system. The 
pattern recognition receptors (PRRs) can identify the evolutio-
narily preserved microbial structures called pathogen- 
associated molecular patterns (PAMPs). As a defense mechan-
ism against the host cells, these viruses (SARS-CoV and MERS- 
CoV) may develop modified membranes derived from host cell 
components such as developing double-membrane vesicles 
that lack or have altered pathogen-associated molecular pat-
terns (PAMPs) hence unrecognizable by the host cell pattern 
recognition receptors (PRRs). This facilitates viral replication 
without their RNA being recognized by the host cell.37 Another 
mechanism seen in MERS infection can be thought of being 
utilized by the SARS-CoV-2 virus to escape the host immunity. 
It has been recognized with MERS infection that the expression 
of genes related to antigen presentation is downregulated upon 
infection, facilitating the virus evade the first checkpoint of 
host immunity.38 Research studies have evidenced the fact 
that nsp can suppress the innate immune response of the host.6
Need for vaccine development
Although remdesivir is available in developed countries as 
a specific antiviral drug that has been shown to be effective in 
reducing symptoms and accelerating recovery from COVID-19 
disease, it is not affordable in most parts of the world and is in 
limited supply, such that much of the world awaits an inex-
pensive and effective antiviral drug. The treatment for COVID- 
19 relies on the management of the symptoms focused on the 
symptomatic management of the patients which include con-
trolling secondary infections by the administration of broad- 
spectrum antibiotics, ventilation, and fluid control.11,34
COVID-19 vaccine development platforms and 
challenges in COVID-19 vaccine development
The public health threat of COVID-19 will remain until 
a potential and effective vaccine is developed.39 Several com-
panies have taken the initiative of developing the vaccine 
against COVID-19 targeting the SARS-CoV2 virus continu-
ously circulating in the human population.40
Various strategies such as live-attenuated virus, viral pro-
teins, viral nucleic acid, virus-like particle, peptide, viral vector 
(replicating and non-replicating), and recombinant protein 
approaches are being used for vaccine development against 
SARS-CoV-2. These strategies have their own associated 
advantages and disadvantages.5,41 Viral antigen-based and 
nucleic acid-based vaccines are safer, but the immunogenic 
potential of these vaccines is less. The nucleic acid-based vac-
cines are the fastest to enter into phase 1 clinical trial, but to 
date, there is no nucleic acid-based vaccine licensed to be used 
in humans. Since safety is a concern with a live-attenuated 
virus, it is risky for the vulnerable older population.41 Nucleic 
acid-based platforms provide wider options for antigen manip-
ulation. Therefore, vaccines based on nucleic acid approaches 
might be considered as one of the important approaches for the 
development of a vaccine for SARS-CoV2.42
Viral vector-based platforms offer advantages such as high 
level of protein expression, stability, and induction of strong 
immune response. Since vaccines based on recombinant pro-
teins are already licensed for several other diseases, the existing 
large-scale production capacity can be utilized for the produc-
tion of vaccines for SARS-CoV-2.42 It is possible that some 
platforms may be more appropriate for a specific group of 
population such as the aged, children, pregnant women or 
immunocompromised patients.
Since our knowledge about the immune responses to the 
vaccines is not entirely established, different strategies should 
be tried for designing a vaccine for COVID-19. Only advances 
and comprehensive research can answer this question about 
selecting the best approach for vaccine development for 
COVID-19. Distinctive challenges for SARS-CoV-2 vaccine 
development include clinical recruitment, defining a correlate 
of protection, and proving efficacy, especially when there is 
public pressure to release a vaccine for general use. Despite the 
development of novel platforms for vaccine development, there 
are several underlying challenges in SARS-CoV-2 vaccine 
development.
Although the viral S protein is a potential immunogen, it is 
essential to evaluate the optimal immune response elicited by 
the antigen. It is still a matter of debate whether the full 
S protein or only the receptor-binding domain is suitable for 
achieving optimal immune response.33 Previous experience 
with SARS and MERS vaccine candidates has raised concerns 
about the exacerbating lung disease, either directly or due to 
antibody-dependent enhancement (ADE). This adverse effect 
may be associated with Th2 response. Production of sub- 
optimal levels of antibody or antibody of low quality can result 
in the phenomenon of ADE that promotes the disease pathol-
ogy. This warrants consideration of ADE in the evaluation of 
safety of the emerging candidate vaccines for SARS-CoV-2. 
Therefore, testing of the vaccine candidates for safety in sui-
table animal models and constant safety monitoring in clinical 
trials is quintessential. It is premature to define a good animal 
model for COVID-19.33
Another major challenge in SARS-CoV-2 vaccine develop-
ment is establishment of correlates of protection. Experience 
with SARS and MERS vaccines may be utilized to establish 
correlates of protection. However, they are still not established. 
The duration of protection and whether a single dose of the 
vaccine is sufficient to elicit the required immune response is 
uncertain.33
Vaccine development is a long process and involves large 
sample sizes for conducting research; it may take years to 
establish a vaccine. Since it is associated with high costs and 
failure rates, the developers take extra precaution and follow 
a strict sequence of steps involving multiple rounds of data 
analysis and strict checks at manufacturing levels. Developing 
a vaccine in an outbreak scenario requires a new strategy of 
executing multiple steps in parallel even before confirmation of 
the outcome of another step.33
The other challenge is faced at the commercial production 
of clinical trial materials. For the novel platforms, large-scale 
production has never been done before. So, it will require 
large-scale production (identification, technology transfer, 
and manufacturing process) without the knowledge of the 
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viability of the vaccine candidate. It is not certain whether these 
novel platforms are scalable and if it is possible to produce 
sufficient quantities using the existing capacity.33
Performing clinical trials during a pandemic is associated 
with the additional challenge of choosing trial sites as it is 
difficult to predict where and when outbreaks will occur. So, 
if multiple vaccines are ready, countries should not be crowded 
with multiple clinical trials. In a pandemic situation where the 
mortality rates are high, people may not consent for rando-
mized controlled trials with placebo.43 One way to tackle this 
problem is utilizing a single-shared control group for testing 
several vaccines simultaneously. In this approach, more people 
will receive an active vaccine.44 Although this approach is 
advantageous, it is associated with statistical complexities. 
Developers may try to avoid direct comparative analysis of 
their vaccine candidates with others.
Finally, there will be a surge of demand for the vaccines 
globally. Hence, serological studies will be needed to establish 
which populations are at higher risks so that they can be 
prioritized for the vaccine allocation.33
Advances in vaccine development for COVID-19
Several companies, research laboratories and universities are 
researching to come up with a vaccine for COVID-19. 
According to WHO, as of August 25, 2020, there are 31 vac-
cines in the clinical evaluation phase (Table 1) and 142 vaccines 
in the preclinical evaluation phase (according to the WHO 
draft, August 25, 2020) (Table 2).45 Out of the 31 candidate 
vaccines in clinical trial phase, 7 have reached phase 3, 3 have 
reached phase 2 clinical trials, and the rest are in phase 1 or 
phase1/2. Of the seven candidate vaccines in phase 3, 
ChAdOx1-S is a single dose intramuscular non-replicating 
viral vector vaccine expressing the SARS-CoV-2 spike protein. 
Other three are inactivated double dose intramuscular SARS- 
CoV-2 vaccines. LNP-encapsulated mRNA and 3 LNP- 
mRNAs are double dose intramuscular RNA vaccines. 
Ad26COVS1 is a double dose intramuscular non-replicating 
viral vector vaccine (Table 1). Three vaccine candidates listed 
in Table 1 are in phase 2 clinical trial. Adenovirus Type 5 
Vector is a single dose intramuscular non-replicating viral 
vector vaccine. Adjuvanted recombinant protein (RBD- 
Dimer) is a double or triple dose intramuscular protein subunit 
vaccine. The other vaccine candidate in phase 2 clinical trial is 
a double dose intramuscular mRNA vaccine (Table 1).
After the vaccine is developed
It is not the only challenge to come up with an effective vaccine 
for COVID-19 in a short period but the most significant 
problem would be getting enough doses of the vaccine to be 
supplied to the countries globally. There is a risk that the more 
affluent countries can monopolize on the supply of COVID-19 
vaccines globally in a similar way that happened with the flu 
pandemic. Therefore, along with focusing on the vaccine devel-
opment, we should focus on containing the spread of the virus. 
Economically weak countries as in Africa would face problems 
in accessing vaccines, as happened with anti-HIV drugs. Due to 
the high rates of HIV drugs, several poor people died in Africa 
not being able to afford it. Therefore, there should be a fair 
distribution of the vaccines if any company succeeds in the race 
of developing a vaccine for COVID-19.
Convalescent plasma therapy
Convalescent plasma therapy is an old concept of separating 
serum from the blood of a patient who has recovered from 
infection and injecting it to another infected patient. The con-
valescent plasma contains the antibodies for the infectious 
pathogen which neutralizes the pathogen in the new recipient 
patient. This therapy can be useful in treating COVID-19 
patients.
The evidence coming from studies that reported the use of 
convalescent plasma therapy in treating past coronavirus infec-
tions such as SARS and MERS compelled the researchers to 
apply this therapy on COVID-19 patients.46–49 Recent studies 
have highlighted the beneficial effects of convalescent plasma 
therapy in critically ill COVID-19 patients.50 Among the five 
critically ill COVID-19 patients who were administered con-
valescent plasma, three patients were discharged upon recov-
ery, and two patients are in the incubation period of 37 days.50 
This treatment modality is associated with some disadvantages. 
Convalescent plasma therapy increases the risk of serum 
related disease and antibody-dependent enhancement of infec-
tion. There is always the risk of transmission of other infectious 
diseases through the serum and the additional risk associated 
with convalescent plasma therapy is the chances of developing 
infection from another viral strain due to antibodies against 
one form of coronavirus.51 All published studies on clinical 
trials with convalescent plasma did not include a negative- 
control group needed to judge the efficacy of the intervention. 
Therefore, the need of the hour is the identification of the 
human monoclonal antibody for a common antigenic deter-
minant/epitope of SARS CoV-2 to prevent COVID-19.
Monoclonal antibody therapy
Human monoclonal antibodies such as 80 R, m396, and 
S230.15 specific for the S1 domain of the SARS CoV have 
been reported to be effective in neutralizing the SARS-CoV 
infections by inhibiting their binding to the ACE receptors on 
the host cells.52 Another study reported that the monoclonal 
antibody CR3014 reduced the rate of replication of SARS-CoV 
genome and inhibited viral shedding, thus wholly prevented 
the virus-induced lung pathology. This antibody also works on 
the principle of inhibiting the binding of SARS-CoV by redu-
cing the affinity of the S1 domain of the virus for the ACE 
receptor on the host cells.53
Since the receptor-binding domain of SARS-CoV-2 differs 
significantly from the SARS-CoV virus, the monoclonal anti-
bodies (as m396, CR3014) targeting the S1 domain of SARS- 
CoV may not be effective in neutralizing the novel SARS-CoV 
-2. A recent study highlighted that the human monoclonal 
antibody CR3022 completely neutralizes both SARS-CoV and 
SARS-CoV-2. Therefore, these monoclonal antibodies can be 
considered for use in the prevention and treatment of COVID- 
19.54 Another study reported that the human monoclonal anti-
body 47D11 neutralizes SARS-CoV-2 by binding to the 
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Table 2. List of 142 candidate vaccines in preclinical evaluation phase.45.
Platform Type of candidate vaccine Developer
Same platform for non-Coronavirus 
candidates
DNA DNA, engineered vaccine inserts compatible with 
multiple delivery systems
DIOSynVax Ltd / University of 
Cambridge
DNA DNA vaccine Ege University
DNA DNA plasmid vaccine RBD&N Scancell/University of Nottingham/ 
Nottingham Trent University
DNA DNA plasmid vaccine S,S1,S2,RBD &N National Research Centre, Egypt
DNA DNA with electroporation Karolinska Institute / Cobra Biologics 
(OPENCORONA Project)
DNA DNA with electroporation Chula Vaccine Research Center
DNA DNA Takis/Applied DNA Sciences/Evvivax
DNA Plasmid DNA, Needle-Free Delivery Immunomic Therapeutics, Inc./EpiVax, 
Inc./PharmaJet
SARS
DNA DNA vaccine BioNet Asia
DNA msDNA vaccine Mediphage Bioceuticals/University of 
Waterloo
DNA DNA vaccine Entos Pharmaceuticals
DNA bacTRL-Spike Symvivo
Inactivated Inactivated + alum KM Biologics JE, Zika
Inactivated Inactivated Selcuk University
Inactivated Inactivated Erciyes University
Inactivated Inactivated whole virus National Research Centre, Egypt
Inactivated Inactivated Beijing Minhai Biotechnology Co., Ltd.
Inactivated TBD Osaka University/ BIKEN/ NIBIOHN
Inactivated Inactivated + CpG 1018 Sinovac/Dynavax
Inactivated Inactivated + CpG 1018 Valneva/Dynavax
Inactivated Inactivated Research Institute for Biological Safety 
Problems, Rep of Kazakhstan
Live Attenuated Virus Codon deoptimized live attenuated vaccines Mehmet Ali Aydinlar University / 
Acıbadem Labmed Health Services 
A.S.
Live Attenuated Virus Codon deoptimized live attenuated vaccines Codagenix/Serum Institute of India HAV, InfA, ZIKV, FMD, SIV, RSV, DENV










Adeno-associated virus vector (AAVCOVID) Massachusetts Eye and Ear/ 




MVA encoded VLP GeoVax/BravoVax LASV, EBOV, MARV, HIV
Non-replicating viral 
vector





MVA-S IDIBAPS-Hospital Clinic, Spain
Non-Replicating Viral 
Vector








2nd Gen E2b- Ad5 Spike, RBD, Nucleocapsid 
Subcutaneous&Oral




Ad5 S (GREVAX™ platform) Greffex MERS
Non-Replicating Viral 
Vector
Oral Ad5 S Stabilitech Biopharma Ltd Zika, VZV, HSV-2 and Norovirus
Non-Replicating Viral 
Vector
adenovirus-based + HLA-matched peptides Valo Therapeutics Ltd
Non-Replicating Viral 
Vector









Dendritic cell-based vaccine University of Manitoba
Non-Replicating Viral 
Vector
parainfluenza virus 5 (PIV5)-based vaccine 
expressing the spike protein
University of Georgia/University of Iowa MERS
Non-Replicating Viral 
Vector
Recombinant deactivated rabies virus 
containing S1
Bharat Biotech/Thomas Jefferson 
University
HeV, NiV, EBOV, LASSA, CCHFV, MERS
Non-Replicating Viral 
Vector
Influenza A H1N1 vector National Research Centre, Egypt
Non-Replicating Viral 
Vector
Inactivated Flu-based SARS-CoV2 vaccine + 
Adjuvant
National Center for Genetic Engineering 
and Biotechnology (BIOTEC) 
/GPO, Thailand
(Continued)
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Table 2. (Continued).
Platform Type of candidate vaccine Developer
Same platform for non-Coronavirus 
candidates
Protein Subunit RBD protein (baculovirus production) + FAR- 
Squalene adjuvant
Farmacológicos Veterinarios SAC 
(FARVET SAC) / Universidad Peruana 
Cayetano Heredia (UPCH)
Protein Subunit Protein Subunit Research Institute for Biological Safety 
Problems, Rep of Kazakhstan
Protein Subunit RBD-protein Mynvax
Protein Subunit Recombinant S protein Izmir Biomedicine and Genome Center
Protein Subunit Peptide + novel adjuvant Bogazici University
Protein Subunit S subunit intranasal liposomal formulation 
with GLA/3M052 adjs.
University of Virginia
Protein Subunit S-Protein (Subunit) + Adjuvant, E coli based 
Expression
Helix Biogen Consult, Ogbomoso & 
Trinity Immonoefficient Laboratory, 
Ogbomoso, Oyo State, Nigeria.
Protein Subunit Protein Subunit S,N,M&S1 protein National Research Centre, Egypt
Protein Subunit Protein Subunit University of San Martin and CONICET, 
Argentina
Protein Subunit RBD protein fused with Fc of IgG + Adj. Chulalongkorn University/GPO, Thailand
Protein Subunit Capsid-like Particle AdaptVac (PREVENT-nCoV consortium)
Protein Subunit Drosophila S2 insect cell expression system 
VLPs
ExpreS2ion
Protein Subunit Peptide antigens formulated in LNP IMV Inc
Protein Subunit S protein WRAIR/USAMRIID
Protein Subunit S protein +Adjuvant National Institute of Infectious Disease, 
Japan/Shionogi/UMN Pharma
Influenza
Protein Subunit VLP-recombinant protein + Adjuvant Osaka University/ BIKEN/ National 
Institutes of Biomedical Innovation, 
Japan
Protein Subunit microneedle arrays S1 subunit Univ. of Pittsburgh MERS
Protein Subunit Peptide Vaxil Bio
Protein Subunit Adjuvanted protein subunit (RBD) Biological E Ltd
Protein Subunit Peptide Flow Pharma Inc Ebola, Marburg, HIV, Zika, Influenza, 
HPV therapeutic vaccine, BreastCA 
vaccine
Protein Subunit S protein AJ Vaccines
Protein Subunit Ii-Key peptide Generex/EpiVax Influenza, HIV, SARS-CoV
Protein Subunit S protein EpiVax/Univ. of Georgia H7N9
Protein Subunit Protein Subunit EPV-CoV-19 EpiVax
Protein Subunit S protein (baculovirus production) Sanofi Pasteur/GSK Influenza, SARS-CoV
Protein Subunit gp-96 backbone Heat Biologics/Univ. Of Miami NSCLC, HIV, malaria, Zika
Protein Subunit Subunit vaccine FBRI SRC VB VECTOR, Rospotrebnadzor, 
Koltsovo
Protein Subunit S1 or RBD protein Baylor College of Medicine SARS
Protein Subunit Subunit protein, plant produced iBio/CC-Pharming
Protein Subunit Recombinant protein, nanoparticles (based 
on S-protein and other epitopes)
Saint-Petersburg scientific research 
institute of vaccines and serums
Protein Subunit COVID-19 XWG-03 
truncated S (spike) proteins
Innovax/Xiamen Univ./GSK HPV
Protein Subunit Adjuvanted microsphere peptide VIDO-InterVac, University of 
Saskatchewan
Protein Subunit Synthetic Long Peptide Vaccine candidate for 
S and M proteins
OncoGen
Protein Subunit Oral E. coli-based protein expression system 
of S and N proteins
MIGAL Galilee Research Institute
Protein Subunit Nanoparticle vaccine LakePharma, Inc.
Protein Subunit Plant-based subunit 
(RBD-Fc + Adjuvant)
Baiya Phytopharm/ Chula Vaccine 
Research Center
Protein Subunit OMV-based vaccine Quadram Institute Biosciences Flu A, plague
Protein Subunit OMV-based vaccine BiOMViS Srl/Univ. of Trento
Protein subunit structurally modified spherical particles of 
the tobacco mosaic virus (TMV)
Lomonosov Moscow State University rubella, rotavirus
Protein Subunit Spike-based University of Alberta Hepatitis C
Protein Subunit Recombinant S1-Fc fusion protein AnyGo Technology
Protein Subunit Recombinant protein Yisheng Biopharma
Protein Subunit Recombinant S protein in IC-BEVS Vabiotech
Protein Subunit Orally delivered, heat stable subunit Applied Biotechnology Institute, Inc.
Protein Subunit Peptides derived from Spike protein Axon Neuroscience SE
Protein Subunit Protein Subunit MOGAM Institute for Biomedical 
Research, GC Pharma
Protein Subunit RBD-based Neovii/Tel Aviv University
Protein Subunit Outer Membrane Vesicle (OMV)-subunit Intravacc/Epivax
Protein Subunit Outer Membrane Vesicle(OMV)-peptide Intravacc/Epivax
Protein Subunit Spike-based (epitope screening) ImmunoPrecise/LiteVax BV
(Continued)
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Table 2. (Continued).
Platform Type of candidate vaccine Developer




Oral Salmonella enteritidis (3934Vac) based 
protein expression system of RBD
Farmacológicos Veterinarios SAC 
(FARVET SAC) / Universidad Peruana 
Cayetano Heredia (UPCH)
Replicating Viral Vector YF17D Vector KU Leuven
Replicating Viral Vector Measles Vector Cadila Healthcare Limited
Replicating Viral Vector Measles Vector FBRI SRC VB VECTOR, Rospotrebnadzor, 
Koltsovo
Replicating Viral Vector Measles Virus (S, N targets) DZIF – German Center for Infection 
Research/CanVirex AG
Zika, H7N9, CHIKV
Replicating Viral Vector Horsepox vector expressing S protein Tonix Pharma/Southern Research Smallpox, monkeypox
Replicating Viral Vector Live viral vectored vaccine based on attenuated 
influenza virus backbone (intranasal)
BiOCAD and IEM Influenza
Replicating Viral Vector Recombinant vaccine based on Influenza A virus, for 
the prevention of COVID-19 (intranasal)
FBRI SRC VB VECTOR, Rospotrebnadzor, 
Koltsovo
Influenza
Replicating Viral Vector Attenuated Influenza expressing 
an antigenic portion of the Spike protein
Fundação Oswaldo Cruz and Instituto 
Buntantan
Influenza
Replicating Viral Vector Influenza vector expressing RBD University of Hong Kong
Replicating Viral Vector Replication-competent VSV chimeric virus 
technology (VSVΔG) delivering the SARS-CoV- 2 
Spike (S) glycoprotein.
IAVI/Merck Ebola, Marburg, Lassa
Replicating Viral Vector Replicating VSV vector-based DC-targeting University of Manitoba
Replicating Viral Vector VSV-S University of Western Ontario HIV, MERS
Replicating Viral Vector VSV-S Aurobindo
Replicating Viral Vector VSV vector FBRI SRC VB VECTOR, Rospotrebnadzor, 
Koltsovo
Replicating Viral Vector VSV-S Israel Institute for Biological Research/ 
Weizmann Institute of Science
Replicating Viral Vector M2-deficient single replication (M2SR) 
influenza vector
UW–Madison/FluGen/Bharat Biotech influenza
Replicating Viral Vector Newcastle disease virus vector (NDV-SARS- 
CoV-2/Spike)
Intravacc/ Wageningen Bioveterinary 
Research/Utrecht Univ.
Replicating Viral Vector Avian paramyxovirus vector (APMV) The Lancaster University, UK
RNA Self-amplifying RNA Gennova
RNA mRNA Selcuk University
RNA LNP-mRNA Translate Bio/Sanofi Pasteur
RNA LNP-mRNA CanSino Biologics/Precision 
NanoSystems
RNA LNP-encapsulated mRNA cocktail encoding 
VLP
Fudan University/ Shanghai JiaoTong 
University/RNACure Biopharma
RNA LNP-encapsulated mRNA encoding RBD Fudan University/ Shanghai JiaoTong 
University/RNACure Biopharma
RNA Replicating Defective SARS-CoV-2 derived 
RNAs
Centro Nacional Biotecnología (CNB- 
CSIC), Spain
RNA LNP-encapsulated mRNA University of Tokyo/ Daiichi-Sankyo MERS
RNA Liposome-encapsulated mRNA BIOCAD
RNA Several mRNA candidates RNAimmune, Inc.
RNA mRNA FBRI SRC VB VECTOR, Rospotrebnadzor, 
Koltsovo
RNA mRNA China CDC/Tongji University/Stermina
RNA LNP-mRNA Chula Vaccine Research Center/ 
University of Pennsylvania
RNA mRNA in an intranasal delivery system eTheRNA
RNA mRNA Greenlight Biosciences
RNA mRNA IDIBAPS-Hospital Clinic, Spain
VLP VLP Bezmialem Vakif University
VLP VLP Middle East Technical University
VLP Enveloped Virus-Like Particle (eVLP) VBI Vaccines Inc. CMV, GBM, Zika
VLP S protein integrated in HIV VLPs IrsiCaixa AIDS Research/IRTA-CReSA/ 
Barcelona Supercomputing 
Centre/Grifols
VLP VLP + Adjuvant Mahidol University/ The Government 
Pharmaceutical Organization 
(GPO)/Siriraj Hospital




VLP Virus-like particle, based on RBD displayed 
on virus-like particles
Saiba GmbH
VLP ADDomerTM multiepitope display Imophoron Ltd and Bristol University’s 
Max Planck Centre
VLP Unknown Doherty Institute
VLP VLP OSIVAX
VLP eVLP ARTES Biotechnology malaria
VLP VLPs peptides/whole virus Univ. of Sao Paulo
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conserved sequence on the receptor-binding domain of the S1B 
protein. These antibodies can slow down the viral infection and 
can impart immunity in the uninfected persons.55 The recep-
tor-binding domain is the best target to develop monoclonal 
antibody treatment to manage or prevent SARS-CoV-2 
infections.
Takeda Pharmaceutical Company based in Japan is in the 
process of preparing a monoclonal antibody mixture, TAK-888 
from the serum of recovered COVID-19 patients to come up 
with a new treatment strategy for COVID-19. Another phar-
maceutical company, Vir Pharmaceuticals, USA, is testing 
antibodies isolated from recovered SARS patients to neutralize 
SARS-CoV-2. This company has also collaborated with 
a China-based company, WuXi Biologics, to develop a serum- 
based therapy to tackle SARS-CoV-2 infection in critically ill 
patients.56
A limitation to the use of convalescent plasma and MAbs is 
that they might benefit hospitalized patients but will not be 
generally useful for the population.
Conclusion
Several companies have initiated the development of antiviral and 
vaccines for COVID-19. Different approaches have been under-
taken to develop an effective vaccine for COVID-19 such as 
attenuated virus, viral proteins, viral nucleic acid, virus-like parti-
cle, peptide, viral vector (replicating and non-replicating), and 
recombinant proteins. However, the most significant challenge 
post-vaccine development will be the fair distribution of the vac-
cines globally. Convalescent plasma therapy and monoclonal anti-
body therapy are also being tested and can be the potential 
therapeutic modality for the management and prevention of 
COVID-19. However, they might benefit only the hospitalized 
patients and will not be generally useful for the population.
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